| PRODUCTSSERVICESCOMPANYCONTACTFAQ |
|
Description: a phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer 5/2007
Also Known As:| 1. | Mok, Y J: 1 article (05/2007) |
| 2. | Sur, H Y: 1 article (05/2007) |
| 3. | Oh, S C: 1 article (05/2007) |
| 4. | Kim, J S: 1 article (05/2007) |
| 5. | Shin, S W: 1 article (05/2007) |
| 6. | Jeen, Y T: 1 article (05/2007) |
| 7. | Chun, H J: 1 article (05/2007) |
| 8. | Park, S S: 1 article (05/2007) |
| 9. | Seo, J H: 1 article (05/2007) |
| 10. | Choi, I K: 1 article (05/2007) |
| 1. | Stomach Neoplasms (Stomach Cancer)
05/21/2007
- "A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer."
Order ALL the reference details at left... |
| 2. | Colorectal Neoplasms (Colorectal Cancer)
04/01/2002
- "Capecitabine/irinotecan combination regimens in colorectal cancer."
Order ALL the reference details at left... |
| 1. | capecitabine (Xeloda)
|
| 2. | irinotecan (Camptosar)
|
CureHunter Patient-Physician Summary Reports collect in one document all the
medications ever reported in the US National Library of Medicine—1949 to the present—to
be effective against your target disease.
CureHunter research summary reports will vary in length from 25 to 250 pages.
Analytic charts allow you and your physicians to see at a glance your
medication options—including new, promising, off-label and experimental
all rated for clinical efficacy.
| Price: | $24.00
& Delivery via
PDF download
updates for 1 year |
| Price: | $490.00
access via web interface 1 year subscription |
| Price: | $45.00
access via "curehunter.com/m" 1 year subscription |